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SUMMARY
To 31st December 1989, 71 persons are known to have attended medical
practitioners in Northern Ireland with a diagnosis ofHuman Immunodeficiency
Virus (HIV) infection. Twenty-one of these persons have had the diagnosis
of Acquired Immune Deficiency Syndrome (AIDS) and 11 have died The
distribution ofreports in the "at risk" categories ofhomosexual/bisexual males,
injecting drug users, heterosexual males and females was significantly different
(p < 0 001) from those reported in the United Kingdom as a whole. Oftests for
HIVinfection carried out inpatients attending thegenitourinary medicine depart-
ment of the Royal Victoria Hospital between 1987-1989, 0 16% have been
positive. Theprognostic value ofthe T4 lymphocyte count atpresentation forthe
subsequent development ofAIDS was significant (p = 0-0011). The commonest
AIDS indicator disease diagnosed was Pneumocystis carinii pneumonia which
was seen in seven of the 21 patients (33%).
INTRODUCTION
The Acquired Immune Deficiency Syndrome (AIDS) was first described in
19811-3 and was soon recognised to be behaving as an infectious disease which
particularly affected homosexual or bisexual men, intravenous drug misusers,
people from central Africa and haemophiliacs. These categories of persons
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became known as "high-risk groups" for development ofthe disease. The cause
ofthesyndromeisnow commonly accepted to behuman immunodeficiency virus
(HIV), first described in 1983.4 The pattern ofthe HIV epidemic has differed from
country tocountry5 and even from citytocity6,7 withina particular country. These
differing emerging patterns seem to depend on local epidemiological factors
specific to each area. We describe the emergence of HIV infection in Northern
Ireland, and weexamine thepatternofdisease that developsand themanagement
of patients.
METHODS
The data was collected from the records of the Genitourinary Medicine Depart-
ments of hospitals in Northern Ireland. Other sources were the Regional Virus
Laboratory, the Northern Ireland Haemophilia Service and the Northern Ireland
Blood Transfusion Service.
The Regional Virus Laboratory began anti-HIV testing in May 1985 and the
Northern Ireland Blood Transfusion Service in October 1985. An anti-globulin
ELISA test (Vironostika anti
-HTLV-II1, Organon, Teknika)isused bytheRegional
Virus Laboratory, and if positive, it is repeated together with two different tests
a competitive ELISA test (Vironostika anti
-HIV Uniform Organon Teknika) and a
gelatin particle agglutination test (Serodia- HIV Fujirebio Inc.). If these tests are
all positive a further serum sample is obtained from the patient and all three tests
are repeated. If the three tests are again positive only then is the patient reported
as confirmed anti-HIV positive. Initially confirmatory tests were done by Dr R S
Fedder of the Section of Virology, Microbiology Department, the Middlesex
Hospital and University College Medical School, London, but they are now done
in the Regional Virus Laboratory. Anti-HIV IgM tests were carried out on sera
from two babies born to anti-HIV positive mothers by Dr P P Mortimer, Virus
Reference Laboratory, Central Public Health Laboratory, Colindale, London.
Retrospective testing of haemophiliacs was done on available sera which had
been stored at -200C in the Regional Virus Laboratory and fresh sera were
obtained from the Department of Haematology, Royal Victoria Hospital.
HIV p24 antigen ELISA tests (Organon Teknika) were performed on sera ofthose
patients entering the Medical Research Council study on the use ofZidovudine in
asymptomatic persons with HIV positive tests, on two babies born to anti-HIV
positive mothers and on other patients when clinically indicated. All tests done
were for HIV-1 antigen or antibody.
Statistical methods used were the Chi-squared test and Fisher's exact probability
test.
HIV cases seen to date
The figures quoted in this article refer to those persons known to the authors who
have been under medical care in Northern Ireland. Some of these persons have
not been resident in Northern Ireland but visit the province on occasions. Others
are persons who have been diagnosed elsewhere but moved to Northern Ireland
for their care. These figures are not the same as the official figures from Northern
Ireland8 which purport to be reports of persons with a first-ever diagnosis of HIV
infection.
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The first known caseofHIVdisease seen in Northern Ireland wasdiagnosed retro-
spectively. The patient, a 50-year-old African male, with hepatitis B infection
was admitted to the Royal Victoria Hospital in 1982 with cerebral symptoms and
a pyrexia of unknown origin. He developed toxic epidermal necrolysis and died
within a few days. A stored sample of blood was subsequently tested when the
HIV antibody test became available, and this was found to be positive. It is
thought thatthis man died ofan AIDS-related illness. Since then there have been
71 known casesof HIVinfection seenin Northern Ireland to31st December 1989.
Table I showsthe epidemiological risk categories (asclassified by the Communic-
able Disease Surveillance Centre) into which these persons belonged. Thirty-four
(48-5%) were homosexual/bisexual malesand eight (11 -4%) were females with
only heterosexual intercourse as their risk factor. Heterosexual males accounted
for six cases (8-6%). Four injecting drug users were seen (5-7%). The percent-
ages for these groups of known epidemiology reported in the U.K.8 were:
homosexual/bisexual males - 58-8%; females with heterosexual intercourse
-5-0%; male heterosexual -3-9%; injecting drug users -18-6%. The
different distribution ofour cases in these four categories isstatistically significant
(p <0-001). One person has been classified as unknown category. Fig 1
illustrates the numbers of new cases seen each year by sex and risk factors.
The 16 haemophiliacs (22-5%) identified as infected with the virus in 1985
when HIV antibody testing became available have been cared for bythe Northern
Ireland Haemophilia Service. Of the 55 remaining persons 49 (69%) have been
cared for by the genitourinary medicine services. The remaining six (8-5%) have
been cared for by other agencies.
TABLE I
Cumulative totals ofHIV-1 antibodypositivepersons seen in Northern Irelandby
exposure category to 31st December 1989
Exposure category Male Female Total
Homosexual/bisexual male 34 34
Injecting drug user 2 2 4
Homosexual/bisexual male and injecting drug user
Haemophiliac 16 16
Blood/components recipient 1 1
Heterosexual contact:
Partner(s) with above risk factor(s) 1 1
Others*
Possibly infected abroad 4 2 6
No evidence of exposure abroad 2 5 7
Undetermined
Child of at-risk/infected parent
Multiple risks 1 1
Other/undetermined 1 1
Totals 60 11 71
*Partner(s) not known to have above risk factor(s).
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To 31st December 1989, 21 persons with the Acquired Immune Deficiency
Syndrome have been looked after in Northern Ireland; of these 11 have died.
TableII showstheriskcategoriestowhichthesepatientsbelonged. Fig2 illustrates
the new cases of AIDS diagnosed each year. The first two cases in females were
seen in 1989.
TABLE II
Cumulative totals ofAIDS cases (deaths) seen in Northern Ireland by exposure
category to 31st December 1989
Exposure category Male Female Total
Homosexual/bisexual male 15 (11) 15 (11)
Injecting drug user
Homosexual/bisexual male and injecting
drug user
Haemophiliac
Blood components recipient: abroad 1 1
UK
Heterosexual contact:
Partner(s) with above risk factor(s)
Others*
Known exposure abroad 3 1 4
No evidence of exposure abroad 1 1
Child of at-risk/infected parent
Multiple risks
Other/undetermined
Totals 19 (11) 2 21 (11)
*Partner(s) not known to have above risk factor(s).
Figures in brackets are positive results.
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Fig 2. Numberofnew casesoftheAcquired
Immune Deficiency Syndrome seen per year
1980-1989 in Northern Ireland.
Testing
The Northern Ireland Blood Trans-
fusion Service has screened approx-
imately 65,000 donors per year,
about 15% ofwhomarenew donors.
Of these, four persons have tested
positive - two men, one of whom
was known to be homosexual and
two women. Subseauent contact
tracing showed that one male partner of this homosexual man and the bisexual
husband of one of the women also had a positive test.
The Regional Virus Laboratory has tested 9,093 other blood samples for HIV
antibodies. One hundred and twenty-three patients with coagulation defectswho
had received treatment with blood products were tested and 16 were positive
(13-8%). If only severely affected patients (less than 0-02 units/decilitre factor
Vill) are included this rises to 25%. Stored sera were available on 11 of the 16
positive patients and when tested showed that seroconversion occurred between
1983 and 1985. The source ofseroconversion in one patient in 1985 was traced
to a batch of heat treated factor VIII which was found retrospectively to be
contaminated with HIV (Fig 3).
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Fig 3. Time of anti-HIV-1 seroconversion in 16 haemophiliac patients.
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Since 1987 the reason for testing patients at the Genitourinary Medicine Clinic in
the Royal Victoria Hospital has been recorded. Ofthe 1433 testscarried outsince
1987, 22 (0X16%) were positive. The epidemiological categories for men and
women tested and the positive results are shown in Table 111. In addition we
carried out an anonymous screen of 500 consecutive attenders at this clinic in
1988 (250 men and 250 women). None of these tests was positive.'0
TABLE III
Testing for HIVantibodies by risk categories in Royal Victoria Hospital
Genitourinary Medicine Clinic - 1987-1989
Male 1987 1988 1989 Total
Homosexual 85 (2) 60 (4) 41 (2) 186 ( 8)
Bisexual 24 9(1) 11 (1) 44( 2)
Heterosexual with risk factor 41 (1) 23 25 (1) 89 ( 2)
Injecting drug users 6 (1) 5 4 (1) 15( 2)
Anxiety 244 203 152 (1) 599( 1)
Needlestick injury 1 2 0 3 ( 0)
Total: 936 (15)
Female 1987 1988 1989 Total
Bisexual contact 7 4 2 13 ( 0)
Heterosexual with risk factors 17 (1) 11 (1) 14 (1) 42 ( 3)
Injecting drug user 0 0 2 (1) 2 ( 1)
Prostitute/IDU 0 1 (1) 0 1 ( 1)
Anxiety 159 126 145 (2) 430( 2)
Children 2 1 0 3 ( 0)
Unknown 4 0 0 4( 0)
Needlestick (unknown source) 0 2 0 2
Total: 497( 7)
Figures in brackets are positive results.
Of the remaining 7,160 tests from various sources in hospital and general
practice, three male patients were found to be positive; one male with hetero-
sexual contact in central Africa, one heterosexual male with a history of blood
transfusion in the USA prior to HIV screening of blood, and one having had
heterosexual contact in Amsterdam. This last patient had positive serology for
syphilis and hepatitis B which are both much commoner infections in homosexual
men - as we have not seen this man at the clinic there may be doubt about this
epidemiological information. It should be noted that the positive tests do not
correlate with the positive diagnoses shown in Fig 1, as six of these persons had
had positive tests outside Northern Ireland which were not repeated.
© The Ulster Medical Society, 1991.
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Five persons have suffered needlestick injuriesfrom HIV positive patients - three
doctors in the genitourinary medicine service and two nurses in the haemophilia
services. None of these has seroconverted during follow-up of between three to
12 months. Two infants have been born to mothers with HIV infection; neither of
these has been shown to have become infected on follow-up.
HIV disease
Manifestations of HIV disease are classified according to revised guidelines laid
down by the Communicable Disease Centre (CDC) in Atlanta, USA11 (Table IV).
Category 1 was only recognised in 198512 and was at first thought to be
an unusual event, although it has now been recognised in over 50% of cases
in some series.'3 Common manifestations are fever, sore throat, lymphadeno-
pathy, macular rash (especially involving the trunk), arthralgia, myalgia and
headaches.13, 14 This illness usually occurs within a few weeks of infection and
predates the seroconversion of the HIV antibody test. It has been suggested that
the more severe and prolonged this acute illness the worse is the prognosis, with
a more rapid decline in T helper cells and onsetoflate HIV disease.13 We have not
observed this illness as yet in any ofour patients, although retrospectively several
reported prior illnesses which would have fitted. One patient had been referred to
a medical outpatient department with this illness, but not surprisingly at that time
the diagnosis was not made; this is an illness which medical practitioners need to
be aware of today.
TABLE IV
CDC classification ofhuman immunodeficiency virus disease manifestation
Group I Acute infection
Group 11 Asymptomatic infection
Group III Persistent generalised lymphadenopathy
Group IV Other disease
Subgroup A Constitutional disease
Subgroup B Neurologic disease
Subgroup C Secondary infectious diseases
Category C - 1 Specified secondary infectious diseases listed in the
CDC surveillance definition for AIDS
Category C - 2 Other specified secondary infectious diseases
Subgroup D Secondary cancers
Subgroup E Other conditions
The majority of patients probably have little or no early symptoms, and those
who do invariably recover and become asymptomatic (Group 11). Persistent
generalised lymphadenopathy (Group 111) is defined as the persistence for over
three months of two or more extra-inguinal lymph nodes greater than one
centimetre in size in persons at risk of HIV infection and having no other cause
for lymphadenopathy. This was felt initially to have prognostic significance but
recent work suggests this is not the case.'5 Onset of late HIV disease (Group IV)
© The Ulster Medical Society, 1991.
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is often marked by constitutional symptoms of malaise, indolent fever, profuse
night sweats, loss ofappetite, persistent diarrhoea and mucocutaneous manifest-
ations which include ichthyosis, seborrhoeic dermatitis and deterioration or
re-emergence of disorders such as fungal infections (often atypical), acne,
psoriasisand eczema. These conditionsare bynomeansspecific. Moresuspicious
disorders are recurrent and persistent herpetic infections especially perianal
disease in homosexual/bisexual males. Herpes zoster which is more severe than
usual, often multidermaloreven bilateralandwhich responds poorlytotreatment,
facial molluscum contagiosum in adults, oral candidiasis and hairy leukoplakia16
(a condition said to bespecific to HIVinfected persons appearing aswhite plaque-
like lesions on the lateral borders of the tongue) are all suspicious. We have seen
each of these conditions in our patients except for psoriasis. Some patients had
consulted general practitioners, hospital doctors and dentists with many of these
problems, sometimes for longer than two years before being diagnosed as HIV
positive, so it is necessary today for all medical disciplines to have a high level of
awareness of the possible significance of such disorders.
AIDS indicator diseases which led to a classification of AIDS17 for the 21 cases
we have managed are shown in Table V along with diseases diagnosed and
treated afterthe indicator disease. Pneumocystis carinlihas been the commonest
diagnosis accounting for 33% ofthe indicator diseases, which is notsignificantly
different from the overall figure of 50% reported from the rest of the UK.8 The
longest surviving AIDS patient we have seen is a man with Kaposi's sarcoma, first
diagnosed in California in 1985. This man is alive and well at the time of writing
this article. The median survival of the 11 patients who have died has been
11 months from the time ofinitial diagnosis ofAIDS, which compares with 9-10
months up to 1987, rising to 18 months in 1987 for patients in England and
Wales.18
TABLE V
Indicator disease forAIDS diagnosis in 21 patients
Initial Subsequent
diagnosis diagnosis
Pneumocystis carinii pneumonia 7 3
Kaposi's sarcoma 2
Oesophageal candida 3
Cytomegalovirus infection 2 2
Persistent herpes simplex infection 2 2
Cryptosporidiosis 1
HIV encephalopathy 1
Cerebral lymphoma 1 3
Intracerebral toxoplasmosis 2
Myelitis 2
Severe peripheral neuropathy 1
Mycobacterium avum intracellular hepatitis 1
Unknown 2
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Unfortunately, no post-mortems have been available in Northern Ireland because
of the inadequacy of mortuary facilities. This has precluded us from making
additional subsequent diagnoses which undoubtedly have been missed, or
confirming some of our presumptive diagnoses such as intracerebral toxoplasma
and lymphomas.
Of the 16 haemophiliac patients infected, three have died, one by suicide, one
from liver failure unrelated to HIV infection and one in whom HIV infection was
contributory. None have had evidence of opportunist infections other than oral
candidiasis affecting fourand pityriasis versicoloraffecting one.Twopatientshave
required treatment for HIV-associated thrombocytopenia, three patients have
required treatment with antiviral agents, and the remaining 10 are asymptomatic
patients in category CDC II.
Prognosis
Predicting the prognosis for people with HIV disease using laboratory markers
has been the subject of intensive research since the disease was first described.
A recent study by Fahey et all9 looked at eight parameters, and concluded that
the most useful laboratory markers were the total T4 lymphocyte count, serum
beta-2-microglobulin and serum neopterin. Of these three laboratory markers
only serial T4 lymphocyte counts have been carried out routinely on HIV positive
patients by the genitourinary medical services. Some authors have noted that a
T cell count level less than 200 x 106/1 at the time of presentation is highly
predictive of development of an AIDS indicator disease.'5,20 In 30 patients
followed up in the genitourinary medicine clinic this parameter gave a good
indication of the likely development of AIDS within a 24 month follow-up
(p =0 0011 Fisher's exact probability test). Nineteen were not evaluated as they
either presented to us with AIDS (8), have been lost to follow-up (5), or were
temporary visitors to Northern Ireland and were not assessed (6). (TableVI). Use
of such markers is of value today along with the clinical state of the patient, as
they allow the clinician to make logical decisions on the introduction of antiviral
and prophylactic therapy.
TABLE VI
Development ofAIDS diagnosis (in brackets) in 30 patients related to T4 cell
count at HIVdiagnosis (p value calculated using Fisher's exactprobability test)
T4 cell count
>200 x 106/L <200 x 106/L
Follow -up
0-12 months 4 (0) 4 (2) NS
13-24 months 6 (0) 1 (1) NS
24+ months 11 (2) 4 (4) p=0Q00011
Antiviral therapy and prophylaxis
The only anti -HIV drug licenced in the United Kingdom is azidothymidine (AZT).
It acts as an inhibitor of reverse transcription which is a vital step in the life cycle
of retroviruses and as a chain terminator in proviral DNA synthesis.2' It has been
© The Ulster Medical Society, 1991.
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shown that azidothymidine inhibits the replication of virus which can lead to
clinical improvement, and objective improvement in laboratory markers.22-24
Unfortunately, the side-effects of this drug may require dose reduction or
discontinuation. The most serious side-effect commonly seen is bone marrow
suppression with a reduction in both red and white cell counts. Serious side-
effects are more common in persons in more advanced stages of the disease.
This would be in keeping with our experience of this drug, as nine out of 10
patients treated for aids have had to have dose reduction orcomplete withdrawal.
On the other hand, there seems to be evidence that HIV positive persons who are
asymptomatic and have good laboratory parameters are more tolerant of this
drug.25 The Medical Research Council in conjunction with the French research
authority INSERM are presently conducting a multi-centre, double-blind study
(Concorde Trial), comparing azidothymidine with placebo in asymptomatic
persons with HIV infection. The Royal Victoria Hospital Genitourinary Medicine
Clinic is a centre in this study and nine patients have been entered for a mean of
44 weeks(range 3to 59). Sofarnone havehad tohave dosage reduction because
of haematological problems. No information is yet available on progression of
disease, but a similar study in America has indicated efficacy in this respect.
Management
Patients other than haemophiliacs with HIV infection have mostly been managed
as outpatients by the Genitourinary Medicine Service at the Royal Victoria
Hospital, although some attend genitourinary clinics held in Altnagelvin and
Coleraine hospitals. These patients have open access to the clinics and the
counselling and social services provided at these centres. A designated HIV clinic
is in operation at the Royal Victoria Hospital. Inpatient management has mostly
been handled by the genitourinary medicine physicians, with close co-operation
with relevant specialists, mostly gastroenterology, immunology, neurology and
respiratory medicine. Someinitial misgivingswerevoiced bynursing, paramedical
and ancillary staff in the care of patients and handling of specimens, but with
explanation of the epidemiology of the infection, familiarity with day to day
management, and the advent of the EHSSB staff education programme,26 these
have largely been allayed, and our experience compares favourably with that of
our colleagues in England and Wales.
With a few exceptions, all our patients have consented to their general practition-
ers being notified of their diagnosis, and in only one instance did that doctor not
wish tocare forthe patient becauseoftheHIVinfection. Wehave nowsuccessfully
managed three patients with AIDS in the community with the co-operation of
the general practitioners, community nursing and social services. Two of these
patients received terminal care at home. Co-operation from the funeral services
has been exemplary, both in the community and for patientswho died in hospital.
CONCLUSION
In Northern Ireland we have been relatively fortunate in having fewer cases of HIV
infection reported per 100,000 of population (4-1 per 105) than in any other
region in the UK.8 We can only speculate on the reasons for this difference.
Homosexual men in the past have left Northern Ireland to express their sexuality
in a more liberal and anonymous community such as London. Another factor is
© The Ulster Medical Society, 1991.
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the low incidence of injecting drug misuse in Northern Ireland which is borne out
from a number of sources.27 Both these factors may have conspired to give a
disproportionate number of heterosexually transmitted cases of HIV infection.
Comparing the overall figures for patients with coagulation defects for the United
Kingdom to those for Northern Ireland there is a 41 % HIV positive rate with an
increase to 59% for severely affected patients,9 compared to 15'8% and 25%
respectively. The lower figure for infection of haemophiliacs in Northern Ireland
may be explained by the use of more factor Vill derived from European sources.
All factor Vill products became infected eventually but the European material
became contaminated at a later date compared to that imported from the United
States of America.
Entering the 1990's is a time of hope for better treatment of HIV disease, with a
consequent improvement of quality of life and survival time for those infected.
Forward predictions of the number of cases up to 1993 for England and Wales
have been revised downwards for homosexual males, which reflects a marked
change of sexual behaviour in this group of people. Little is known of the sexual
behaviour of the population of Northern Ireland, although one study indicated
little change in homosexual risk behaviour in Northern Ireland over the period
1981 -1987 despite a greater awareness in this population of HIV infection and a
significantly greater resolve to change sexual behaviour because of perceived
risk.28 Because of this, and the fact that comparison between Northern Ireland
and England and Wales maynotbevalid, wehave chosen nottomake projections
for the 1990's in Northern Ireland. With the foregoing evidence, an awareness of
HIV disease in the community is essential for all medical practitioners, and we
express the hope that people in our population will recognise the risk of HIV
transmission and take appropriate action in their own lives to avoid infection.
We thank Dr Chris Patterson for statistical advice, Mr Mervyn Killen for Figure 3 and Miss Ellen Smith
and Mrs Marie Loughran for preparation of the manuscript.
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